Photo caption: Colorized scanning electron micrograph of Middle East Respiratory Syndrome virus particles
Credit: NAIID
Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. In view of the ongoing COVID-19 pandemic, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV prevention and treatment solutions.
NIAID researchers have identified and developed neutralizing monoclonal antibodies (nMAbs) against MERS-CoV, which target the spike (S) glycoprotein on the coronavirus surface that mediates viral entry into host cells. These novel antibodies target different regions of the S protein and, when administered in combination, reduce the possibility of viral escape. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways, and severe disease in challenge studies with mice. In addition, these nMAbs have potential application for use in assays for detecting MERS-CoV S protein in infected patients or animals.
Read about this exciting licensing opportunity at https://lnkd.in/ezccBDr or contact Amy Petrik, Ph.D., 240-627-3721; amy.petrik@nih.gov.
NIAID researchers have identified and developed neutralizing monoclonal antibodies (nMAbs) against MERS-CoV, which target the spike (S) glycoprotein on the coronavirus surface that mediates viral entry into host cells. These novel antibodies target different regions of the S protein and, when administered in combination, reduce the possibility of viral escape. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways, and severe disease in challenge studies with mice. In addition, these nMAbs have potential application for use in assays for detecting MERS-CoV S protein in infected patients or animals.
Read about this exciting licensing opportunity at https://lnkd.in/ezccBDr or contact Amy Petrik, Ph.D., 240-627-3721; amy.petrik@nih.gov.
No hay comentarios:
Publicar un comentario